JP2001516332A - 哺乳動物における真菌感染を治療するための方法および組成物 - Google Patents

哺乳動物における真菌感染を治療するための方法および組成物

Info

Publication number
JP2001516332A
JP2001516332A JP51057697A JP51057697A JP2001516332A JP 2001516332 A JP2001516332 A JP 2001516332A JP 51057697 A JP51057697 A JP 51057697A JP 51057697 A JP51057697 A JP 51057697A JP 2001516332 A JP2001516332 A JP 2001516332A
Authority
JP
Japan
Prior art keywords
nikkomycin
candida
sustained release
nicomycin
saline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51057697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516332A5 (cg-RX-API-DMAC7.html
Inventor
ヘクター，リチャード，エフ．
サボウニ，アクラム
Original Assignee
シャマーン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャマーン ファーマシューティカルズ，インコーポレーテッド filed Critical シャマーン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2001516332A publication Critical patent/JP2001516332A/ja
Publication of JP2001516332A5 publication Critical patent/JP2001516332A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP51057697A 1995-08-28 1996-08-28 哺乳動物における真菌感染を治療するための方法および組成物 Ceased JP2001516332A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52028995A 1995-08-28 1995-08-28
US520,289 1995-08-28
US08/697,706 US5789387A (en) 1995-08-28 1996-08-27 Methods and compositions for treating fungal infections in mammals
US697,706 1996-08-27
PCT/US1996/013916 WO1997007802A1 (en) 1995-08-28 1996-08-28 Methods and compositions for treating fungal infections in mammals

Publications (2)

Publication Number Publication Date
JP2001516332A true JP2001516332A (ja) 2001-09-25
JP2001516332A5 JP2001516332A5 (cg-RX-API-DMAC7.html) 2004-09-09

Family

ID=27060105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51057697A Ceased JP2001516332A (ja) 1995-08-28 1996-08-28 哺乳動物における真菌感染を治療するための方法および組成物

Country Status (10)

Country Link
US (1) US5789387A (cg-RX-API-DMAC7.html)
EP (1) EP0850063A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001516332A (cg-RX-API-DMAC7.html)
KR (1) KR19990044174A (cg-RX-API-DMAC7.html)
CN (1) CN1256631A (cg-RX-API-DMAC7.html)
AU (1) AU6906096A (cg-RX-API-DMAC7.html)
BR (1) BR9610134A (cg-RX-API-DMAC7.html)
CA (1) CA2230856A1 (cg-RX-API-DMAC7.html)
IL (1) IL123498A0 (cg-RX-API-DMAC7.html)
WO (1) WO1997007802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233250T2 (de) * 1991-05-06 2004-08-26 The Procter & Gamble Company, Cincinnati Kombinationen aus calzium und vitamin d
WO2012094360A2 (en) 2011-01-04 2012-07-12 Gordon Chiu Biotherapeutics for the treatment of infectious diseases
JP6502930B2 (ja) * 2013-06-21 2019-04-17 イミジン， インコーポレイテッド 血液解析

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928137A1 (de) * 1979-07-12 1981-02-05 Bayer Ag Neue nikkomycine, ein verfahren zu ihrer herstellung sowie ihre verwendung als schaedlingsbekaempfungsmittel
DE3020722A1 (de) * 1980-05-31 1981-12-10 Bayer Ag, 5090 Leverkusen Verfahren zur anreicherung von nikkomycin-gemischen
US4851389A (en) * 1987-03-25 1989-07-25 Miles Laboratories, Inc. Use of nikkomycin compounds to treat infections of dimorphic, highly chitinous fungi
US5521153A (en) * 1987-10-02 1996-05-28 Ciba-Geigy Corporation Synergistic antifungal protein and compositions containing same
US5096889A (en) * 1987-11-09 1992-03-17 Bayer Ag Antimycotic compositions of nikkomycin compounds and azole antimycotics
US5006513A (en) * 1987-11-09 1991-04-09 Miles Inc. Antimycotic compositions of nikkomycin compounds and azole antimycotica
US5134126A (en) * 1987-11-09 1992-07-28 Bayer Ag Antimycotic compositions of nikkomycin compounds and azole antimycotics
US5194427A (en) * 1987-11-09 1993-03-16 Bayer Ag Antimycotic compositions of nikkomycin compounds and azole antimycotics
ES2039273T3 (es) * 1987-11-09 1993-09-16 Bayer Ag Compuestos antimicoticos a base de combinaciones de nicomicina y azol antimicotico.
US4914087A (en) * 1988-02-29 1990-04-03 Bayer Ag Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics
US5091375A (en) * 1988-02-29 1992-02-25 Bayer Ag Nikkomycin derivatives
US5149795A (en) * 1988-10-03 1992-09-22 Bayer Ag Nikkomycin derivatives
US5019560A (en) * 1988-10-03 1991-05-28 Bayer Ag Method for treating fungal infections with nikkomycin derivatives
EP0460753A3 (en) * 1990-06-07 1992-04-15 Mogen International N.V. New antifungal preparations, process for making such preparations, process for obtaining plants with decreased susceptibility to fungi
US5326561A (en) * 1992-12-15 1994-07-05 Cornell Research Foundation, Inc. Antifungal synergistic combination of enzyme fungicide and non-enzymatic fungicide and use thereof
US5238926A (en) * 1991-08-20 1993-08-24 Schering Corporation Anti-fungal agents
US5236900A (en) * 1991-08-20 1993-08-17 Schering Corporation Anti-fungal agents
US5346898A (en) * 1992-06-18 1994-09-13 Schering Corporation Anti-fungal uracil compounds
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5614377A (en) * 1994-02-28 1997-03-25 Myco Pharmaceuticals, Incorporated Methods for identifying inhibitors of fungal pathogenicity

Also Published As

Publication number Publication date
KR19990044174A (ko) 1999-06-25
IL123498A0 (en) 1998-09-24
MX9801538A (es) 1998-05-31
WO1997007802A1 (en) 1997-03-06
CN1256631A (zh) 2000-06-14
US5789387A (en) 1998-08-04
EP0850063A4 (cg-RX-API-DMAC7.html) 1998-08-05
BR9610134A (pt) 1999-07-27
CA2230856A1 (en) 1997-03-06
AU6906096A (en) 1997-03-19
EP0850063A1 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
Yamamoto et al. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock
AL-Khikani Pulmonary mycoses treated by topical amphotericin B
US20220202730A1 (en) 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
AU9385898A (en) Long acting injectable formulations containing hydrogenated castor oil
Perfect et al. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis
Araneo et al. Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury
Bechert et al. Pharmacokinetics of terbinafine after single oral dose administration in red-tailed hawks (Buteo jamaicensis)
TW200930381A (en) Compositions and methods for the treatment of bladder cancer
JP2915296B2 (ja) 抗真菌製剤
CN121102139A (zh) 7-脱氢胆固醇脂质体及其应用
KR20010072228A (ko) 위장 독성이 감소된 캠프토테신 유도체의 용도
US5789387A (en) Methods and compositions for treating fungal infections in mammals
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
Allendoerfer et al. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis
KR20120029328A (ko) 높은 방부력을 제공하는 오일 주사 제형
Drouhet Antifungal agents
JP5981430B2 (ja) ハートワーム感染を治療するための組成物
CN107106691A (zh) 制剂
JP2025527861A (ja) チオストレプトン投薬レジメン
JP2020536092A (ja) 細菌感染症の治療方法
EP1317922B1 (fr) Preparation antipyretique renfermant du xylitol
US4348407A (en) Orally active tolciclate and tolnaftate
US7199156B2 (en) Composition and method to treat solid tumors
CN119157869B (zh) 一种dha@zif-8在治疗小鼠脑型疟中的应用
RU2445954C2 (ru) Комплекс для лечения отравлений, содержащий фенотиазиновое соединение, и способы лечения отравлений

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070326

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070807